Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.

The pharmaceutical industry is witnessing something of a renaissance right now. Just a couple of years ago, drug companies banded together and created multiple vaccine treatments used to combat COVID-19.While these breakthrough medications captivated the minds of investors, new growth opportunities have emerged in other areas. In particular, weight loss treatments used for diabetes and obesity now appear to be the hottest ticket in town among pharma companies.Novo Nordisk is the brains behind popular glucagon-like peptide 1 (GLP-1) agonists including Ozempic, Wegovy, Rybelsus, and Saxenda. Eli Lilly has recently entered the weight loss space through its competing GLP-1 medications, Mounjaro and Zepbound.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool